[go: up one dir, main page]

AR080056A1 - Derivados de ciclohexil-amida como antagonistas de los receptores de crf - Google Patents

Derivados de ciclohexil-amida como antagonistas de los receptores de crf

Info

Publication number
AR080056A1
AR080056A1 ARP110100296A ARP110100296A AR080056A1 AR 080056 A1 AR080056 A1 AR 080056A1 AR P110100296 A ARP110100296 A AR P110100296A AR P110100296 A ARP110100296 A AR P110100296A AR 080056 A1 AR080056 A1 AR 080056A1
Authority
AR
Argentina
Prior art keywords
alkyl
halogen
hydrogen
link
ciclohexil
Prior art date
Application number
ARP110100296A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR080056A1 publication Critical patent/AR080056A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Addiction (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Composicion farmacéutica y usos. Reivindicacion 1: Un compuesto de la formula (1), en donde R1 es fenilo o un heteroarilo de 6 miembros, cada uno de los cuales puede estar opcionalmente sustituido por uno o más sustituyentes seleccionados a partir del grupo alquilo C1-10, alcoxilo C1-10, halogeno y halo-alquilo C1-10; X1 es un enlace o es -CR2R3-, -NR4-, -O- o -CR5R6CR7R8-; X2 es un enlace o es -CR9R10- o -CR11R12CR13R14-; en el entendido de que, cuando X1 es -CR5R6CR7R8-, entonces X2 no es -CR11R12CR13R14- y solamente uno de X1 y X2 puede ser un enlace; A1 es -N- o CR15; A2 es CR16; A3 es -N- o CR17; A4 es -N- o CR18, en el entendido de que no más de dos de A1, A3 y A4 es -N-; o R2, R3, R5, R6, R7, R8, R9, R10, R11, R12, R13 y R14, los cuales pueden ser iguales o diferentes, son cada uno hidrogeno, alquilo C1-10 o halogeno, o un par de R2 y R3, R5 y R6, R7 y R8, R9 y R10, R11 y R12, y R13 y R14, forman juntos un anillo carbocíclico o heterocíclico saturado de 3 a 6 miembros que contiene 1 o 2 heteroátomos; R4 es hidrogeno o alquilo C1-10; R15, R16, R17 y R18, los cuales pueden ser iguales o diferentes, son cada uno hidrogeno, alquilo C1-10, alcoxilo C1-10, halogeno o halo-alcoxilo C1-10; e isomeros del mismo; en forma libre o en forma de sal. Reivindicacion 15: Un compuesto de la formula (2), en donde X1, X2, A1, A2, A3 y A4 son cada uno como se definen en la reivindicacion 1; e isomeros del mismo; en forma libre o en forma de sal.
ARP110100296A 2010-02-01 2011-01-28 Derivados de ciclohexil-amida como antagonistas de los receptores de crf AR080056A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30020010P 2010-02-01 2010-02-01
US201061424272P 2010-12-17 2010-12-17

Publications (1)

Publication Number Publication Date
AR080056A1 true AR080056A1 (es) 2012-03-07

Family

ID=44319899

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110100296A AR080056A1 (es) 2010-02-01 2011-01-28 Derivados de ciclohexil-amida como antagonistas de los receptores de crf

Country Status (3)

Country Link
US (1) US20110201629A1 (es)
AR (1) AR080056A1 (es)
WO (1) WO2011092293A2 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20150965A1 (es) 2012-10-11 2015-06-20 Hoffmann La Roche Azaindolinas
JPWO2015012400A1 (ja) * 2013-07-26 2017-03-02 大正製薬株式会社 グリシントランスポーター阻害物質
MX389004B (es) 2014-01-21 2025-03-20 Neurocrine Biosciences Inc Antagonistas de receptor del factor de liberación de corticotropina (crf1) para el tratamiento de hiperplasia adrenal congénita.
JOP20170153A1 (ar) 2016-07-15 2019-01-30 Lilly Co Eli نظائر urocortin-2 جديدة معدلة بحمض دهني لعلاج داء السكري وأمراض الكلى المزمنة
GB201700692D0 (en) 2017-01-16 2017-03-01 Salvensis Novel compounds and their use in the treatment of schistosomiasis
KR20200035035A (ko) 2017-07-31 2020-04-01 노파르티스 아게 코카인 사용 감소 또는 코카인 사용 재발 예방에 있어서 마보글루란트의 용도
JP7357932B2 (ja) * 2018-04-09 2023-10-10 ラクオリア創薬株式会社 Ｃｒｈｒ２拮抗薬としての縮合環状尿素誘導体
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
MA54395A (fr) 2018-12-07 2022-03-16 Neurocrine Biosciences Inc Antagoniste du récepteur crf1, formulations pharmaceutiques et formes solides correspondantes pour le traitement de l'hyperplasie surrénalienne congénitale
US11384083B2 (en) 2019-02-15 2022-07-12 Incyte Corporation Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
TW202100520A (zh) 2019-03-05 2021-01-01 美商英塞特公司 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
WO2020223469A1 (en) 2019-05-01 2020-11-05 Incyte Corporation N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
AU2020328025A1 (en) 2019-08-14 2022-03-03 Incyte Corporation Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors
WO2021062246A1 (en) 2019-09-27 2021-04-01 Neurocrine Biosciences, Inc. Crf receptor antagonists and methods of use
CN119930611A (zh) 2019-10-11 2025-05-06 因赛特公司 作为cdk2抑制剂的双环胺
WO2021145401A1 (en) * 2020-01-15 2021-07-22 Raqualia Pharma Inc. Spiroheterocyclic derivatives as crhr2 antagonist
WO2022071484A1 (en) * 2020-09-30 2022-04-07 Raqualia Pharma Inc. 3-hydroxyoxindole derivatives as crhr2 antagonist
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors

Family Cites Families (195)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
US6403599B1 (en) 1995-11-08 2002-06-11 Pfizer Inc Corticotropin releasing factor antagonists
TW544448B (en) 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
GB9802251D0 (en) 1998-02-03 1998-04-01 Ciba Geigy Ag Organic compounds
WO2000020001A1 (en) 1998-10-02 2000-04-13 Novartis Ag Mglur5 antagonists for the treatment of pain and anxiety
US6525203B1 (en) 1999-03-12 2003-02-25 Bristol-Myers Squibb Company Heterocyclic aromatic compounds useful as growth hormone secretagogues
CA2409006A1 (en) * 2000-05-31 2001-12-06 Warner-Lambert Company Biciclic cyclohexylamines and their use as nmda receptor antogonists
GB0028702D0 (en) 2000-11-24 2001-01-10 Novartis Ag Organic compounds
PL363907A1 (en) 2001-03-26 2004-11-29 Novartis Ag Fused pyridine derivatives for use as vanilloid receptor antagonists for treating pain.
CN1551760A (zh) 2001-03-29 2004-12-01 ҩ��Э�͹�˾ 用于治疗组织炎症和癌变的鸟苷酸环化酶受体拮抗剂
JP3894035B2 (ja) 2001-07-04 2007-03-14 東レ株式会社 炭素繊維強化基材、それからなるプリフォームおよび複合材料
TW200306839A (en) 2002-02-06 2003-12-01 Novartis Ag Quinazolinone derivatives and their use as CB agonists
US6696468B2 (en) 2002-05-16 2004-02-24 Dainippon Pharmaceutical Co., Ltd. (s)-4-amino-5-chloro-2-methoxy-n-[1-[1-(2-tetrahydrofuryl-carbonyl)-4-piperidinylmethyl]-4-piperidinyl]benzamide, process for the preparation thereof, pharmaceutical composition containing the same, and intermediate therefor
SE0201940D0 (sv) 2002-06-20 2002-06-20 Astrazeneca Ab New combination II
DOP2003000703A (es) 2002-09-20 2004-03-31 Pfizer Compuestos de imidazopiradina como agonistas del receptor 5-ht4
GB0223730D0 (en) 2002-10-11 2002-11-20 Novartis Ag Organic compounds
PE20040844A1 (es) 2002-11-26 2004-12-30 Novartis Ag Acidos fenilaceticos y derivados como inhibidores de la cox-2
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
GB0302876D0 (en) 2003-02-07 2003-03-12 Novartis Ag Organic compounds
EP1631260A2 (en) 2003-02-28 2006-03-08 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
JP2004277319A (ja) 2003-03-14 2004-10-07 Dainippon Pharmaceut Co Ltd １−（４−ピペリジニルメチル）ピペリジニルアミド誘導体およびそれを含有する医薬組成物
JP2004277318A (ja) 2003-03-14 2004-10-07 Dainippon Pharmaceut Co Ltd １−（１−置換カルボニル−４−ピペリジニルメチル）ピペリジン誘導体およびそれを含有する医薬組成物
PT1644021E (pt) 2003-06-13 2013-01-30 Ironwood Pharmaceuticals Inc Métodos e composições para o tratamento de distúrbios gastrointestinais
US7491695B2 (en) 2003-06-18 2009-02-17 Tranzyme Pharma Inc. Methods of using macrocyclic modulators of the ghrelin receptor
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
EP1505064A1 (en) 2003-08-05 2005-02-09 Bayer HealthCare AG 2-Aminopyrimidine derivatives
CN1835753A (zh) 2003-08-12 2006-09-20 弗·哈夫曼-拉罗切有限公司 作为促皮质释放素(cfr)拮抗剂的螺－取代的四氢喹唑啉
EP1656354B1 (en) 2003-08-12 2007-09-26 F.Hoffmann-La Roche Ag Tetrahydroquinazoline derivatives as cfr antagonists
WO2005068448A1 (en) 2003-08-29 2005-07-28 Ionix Pharmaceuticals Limited Sulfonamides antagonising n-type calcium channels
KR100738784B1 (ko) 2003-09-03 2007-07-12 화이자 인코포레이티드 5-ｈｔ4 수용체 효능 활성을 갖는 벤즈이미다졸론
AU2004274403A1 (en) 2003-09-03 2005-03-31 Aventis Pharmaceuticals Inc. 5-aryl-Pyrazolo(4,3-d)pyrimidines, pyridines, and pyrazines and related compounds
AP2006003559A0 (en) 2003-09-05 2006-04-30 Neurogen Corp Ventis Pharmaceuticals Inc Heteroaryl fused pyridines, pyrazines and pyrimidines as CRF 1 receptor ligands
JP2005082508A (ja) 2003-09-05 2005-03-31 Dainippon Pharmaceut Co Ltd ２−アルコキシ−６−アミノ−５−ハロゲノ−ｎ−（１−置換−４−ピペリジニル）ピリジン−３−カルボキサミド誘導体およびそれを含有する医薬組成物
CA2538026A1 (en) 2003-09-09 2005-03-24 Ono Pharmaceutical Co., Ltd. Crf antagonists and heterobicyclic compounds
GB0322612D0 (en) 2003-09-26 2003-10-29 Novartis Ag Organic compounds
AU2004278372B2 (en) 2003-09-30 2010-02-18 Janssen Pharmaceutica N.V. Quinoxaline compounds
BRPI0414918A (pt) 2003-09-30 2006-11-07 Janssen Pharmaceutica Nv compostos de benzoimidazola
JP2005104896A (ja) 2003-09-30 2005-04-21 Dainippon Pharmaceut Co Ltd ２−アルコキシ−６−アミノ−５−ハロゲノピリジン−３−カルボキサミド誘導体およびそれを含有する医薬組成物
JP2007510645A (ja) 2003-10-31 2007-04-26 アストラゼネカ アクチボラグ アルキン類ｉ
CA2543707A1 (en) 2003-10-31 2005-05-19 Takeda Pharmaceutical Company Limited Nitrogen-containing fused heterocyclic compounds
NZ547044A (en) 2003-11-10 2010-05-28 Merck Sharp & Dohme Substituted triazoles as sodium channel blockers
US7208596B2 (en) 2003-11-25 2007-04-24 Bristol-Myers Squibb Pharma Company Processes for the preparation of pyrazolo[1,5-a]-1,3,5-triazines and intermediates thereof
WO2005054239A1 (en) 2003-12-05 2005-06-16 Bayer Healthcare Ag 2-aminopyrimidine derivatives
US7211568B2 (en) 2003-12-18 2007-05-01 Kosan Biosciences Incorporated 9-Desoxoerythromycin compounds as prokinetic agents
ES2303969T3 (es) 2003-12-19 2008-09-01 Astrazeneca Ab 5-fluoro- y cloro-piridin-2-il-tetrazoles como ligandos del receptor metabotropico de glutamato de tipo 5.
JP2005206590A (ja) 2003-12-25 2005-08-04 Mitsubishi Pharma Corp ナトリウムチャネルサイト２選択的阻害剤
DK2194053T3 (da) 2004-01-07 2013-07-01 Armetheon Inc Methoxypiperidinderivater til brug i behandling af gastrointestinale forstyrrelser og forstyrrelser i centralnervesystemet.
TW200530181A (en) 2004-01-13 2005-09-16 Bristol Myers Squibb Co Heterocyclic compounds useful as growth hormone secretagogues
EP1713797B1 (en) 2004-01-29 2008-03-05 Pfizer, Inc. 1-isopropyl-2-oxo-1,2-dihydropyridine-3-carboxamide derivatives having 5-ht4 receptor agonistic activity
WO2005077345A1 (en) 2004-02-03 2005-08-25 Astrazeneca Ab Compounds for the treatment of gastro-esophageal reflux disease
WO2005077373A2 (en) 2004-02-03 2005-08-25 Astrazeneca Ab Treatment of gastro-esophageal reflux disease (gerd)
MY152888A (en) 2004-02-18 2014-11-28 Astrazeneca Ab Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists.
TW200604183A (en) 2004-02-18 2006-02-01 Astrazeneca Ab Triazole compounds and their use as metabotropic glutamate receptor antagonists
RU2372347C2 (ru) 2004-02-18 2009-11-10 Астразенека Аб Соединения тетразола и их применение в качестве антагонистов метаботропного рецептора глутамата
US7585881B2 (en) 2004-02-18 2009-09-08 Astrazeneca Ab Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
CA2555272A1 (en) 2004-02-18 2005-09-01 Astrazeneca Ab Polyheterocyclic compounds and their use as metabotropic glutamate receptor antagonists
TW200533348A (en) 2004-02-18 2005-10-16 Theravance Inc Indazole-carboxamide compounds as 5-ht4 receptor agonists
CA2556268A1 (en) 2004-02-18 2005-09-01 Astrazeneca Ab Acetylinic piperazine compounds and their use as metabotropic glutamate receptor antagonists
TW200538108A (en) 2004-02-19 2005-12-01 Astrazeneca Ab Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists
TW200538180A (en) 2004-02-20 2005-12-01 Astrazeneca Ab New compounds
WO2005092882A1 (en) 2004-03-01 2005-10-06 Pfizer Japan, Inc. 4-amino-5-halogeno-benzamide derivatives as 5-ht4 receptor agonists for the treatment of gastrointestinal, cns, neurological and cardiovascular disorders
US7087749B2 (en) 2004-03-11 2006-08-08 Adolor Corporation Substituted piperidine compounds and methods of their use
EP1737297B1 (en) 2004-03-25 2012-12-19 Janssen Pharmaceutica NV Imidazole compounds
US20080280873A1 (en) 2004-03-29 2008-11-13 Jun Liang Biaryl Substituted Pyrazinones as Sodium Channel Blockers
CA2561801A1 (en) 2004-04-02 2005-10-20 Elixir Pharmaceuticals, Inc. Sulfonamides and uses thereof
TWI351282B (en) 2004-04-07 2011-11-01 Theravance Inc Quinolinone-carboxamide compounds as 5-ht4 recepto
US20080015196A1 (en) 2004-04-16 2008-01-17 Neurogen Corporation Imidazopyrazines, Imidazopyridines, and Imidazopyrimidines as Crf1 Receptor Ligands
GB0412768D0 (en) 2004-06-08 2004-07-07 Novartis Ag Organic compounds
GB0412769D0 (en) 2004-06-08 2004-07-07 Novartis Ag Organic compounds
AU2005254800B2 (en) 2004-06-15 2010-12-09 Pfizer Inc. Benzimidazolone carboxylic acid derivatives
AR049300A1 (es) 2004-06-15 2006-07-12 Schering Corp Compuestos triciclicos antagonistas de mglur1 como agentes terapeuticos
SE0401653D0 (sv) 2004-06-24 2004-06-24 Astrazeneca Ab New compounds
WO2006006740A1 (ja) 2004-07-14 2006-01-19 Japan Tobacco Inc. ３−アミノベンズアミド化合物及びバニロイド受容体１型(ｖｒ１)活性阻害剤
MX2007000480A (es) 2004-07-15 2007-03-29 Japan Tobacco Inc Compuesto de benzamida fusionado e inhibidor de actividad de receptor de vainilloide 1.
US20080039430A1 (en) 2004-07-19 2008-02-14 Ali Ouaissi Pharmaceutical Compositions For The Treatment Of Leishmaniasis
WO2006010629A1 (en) 2004-07-28 2006-02-02 Glaxo Group Limited Piperazine derivatives useful for the treatment of gastrointestinal disorders
ITMI20041566A1 (it) 2004-07-30 2004-10-30 Indena Spa "trpv1 agonisti, formulazioni che li contengono e loro usi"
WO2006016218A1 (en) 2004-08-03 2006-02-16 Pfizer Japan Inc. Aryl or heteroaryl carbonyl derivatives derivatives useful as vanilloid receptor 1 (vr1) antagonists
WO2006023757A2 (en) 2004-08-19 2006-03-02 University Of Virginia Patent Foundation Novel tricyclic, bicyclic, monocyclic, and acyclic amines as potent sodium channel blocking agents
EP1789413A1 (en) 2004-09-13 2007-05-30 Amgen Inc. Vanilloid receptor ligands and their use in treatments
GB0420424D0 (en) 2004-09-14 2004-10-20 Ionix Pharmaceuticals Ltd Therapeutic compounds
US20060063792A1 (en) 2004-09-17 2006-03-23 Adolor Corporation Substituted morphinans and methods of their use
SE0402284D0 (sv) 2004-09-21 2004-09-21 Astrazeneca Ab New heterocyclic amides
CA2579242A1 (en) 2004-09-27 2006-04-06 Elixir Pharmaceuticals, Inc. Sulfonamides and uses thereof
WO2006038594A1 (ja) 2004-10-04 2006-04-13 Ono Pharmaceutical Co., Ltd. Ｎ型カルシウムチャネル阻害薬
CN101223166B (zh) 2004-10-07 2011-10-19 默沙东公司 噻唑基mglur5拮抗剂及其应用方法
EP1799661A1 (en) 2004-10-08 2007-06-27 AstraZeneca AB New hydroxymethylbenzothiazoles amides
US8143425B2 (en) 2004-10-12 2012-03-27 Bristol-Myers Squibb Company Heterocyclic aromatic compounds useful as growth hormone secretagogues
AU2005295752A1 (en) 2004-10-15 2006-04-27 Amgen Inc. Imidazole derivatives as vanilloid receptor ligands
GB0519957D0 (en) 2005-09-30 2005-11-09 Sb Pharmco Inc Chemical compound
ES2326827T3 (es) 2004-10-19 2009-10-20 Smithkline Beecham (Cork) Limited Anatagonistas del receptor de crf y metodos relacionados.
EP1807418A2 (en) 2004-10-22 2007-07-18 Amgen, Inc Substituted nitrogen-containing heterocycles as vanilloid receptor ligands and their uses as medicament
WO2006048771A1 (en) 2004-11-04 2006-05-11 Addex Pharmaceuticals Sa Novel tetrazole derivatives as positive allosteric modulators of metabotropic glutamate receptors
JP5042028B2 (ja) 2004-11-05 2012-10-03 セラヴァンス， インコーポレーテッド キノリノン−カルボキサミド化合物
ES2332808T3 (es) 2004-11-05 2010-02-12 Theravance, Inc. Compuestos agonistas del receptor 5-ht4.
AU2005303893A1 (en) 2004-11-11 2006-05-18 Argenta Discovery Ltd Pyrimidine compounds as histamine modulators
US20060111416A1 (en) 2004-11-24 2006-05-25 Lane Charlotte A L Octahydropyrrolo[3,4-C]pyrrole derivatives
CN101443327A (zh) 2004-11-24 2009-05-27 艾博特公司 抑制香草素受体亚型1（vr1）受体的苯并二氢吡喃基脲化合物及其用途
WO2006058338A2 (en) 2004-11-29 2006-06-01 Janssen Pharmaceutica N.V. 4 - piperidinecarboxamide derivatives as modulators of vanilloid vr1 receptor
US7875627B2 (en) 2004-12-07 2011-01-25 Abbott Laboratories Thienopyridyl compounds that inhibit vanilloid receptor subtype 1 (VR1) and uses thereof
US20060128710A1 (en) 2004-12-09 2006-06-15 Chih-Hung Lee Antagonists to the vanilloid receptor subtype 1 (VR1) and uses thereof
US7615570B2 (en) 2004-12-13 2009-11-10 Abbott Laboratories Antagonists to the vanilloid receptor subtype 1 (VR1) and uses thereof
SE0403118D0 (sv) 2004-12-21 2004-12-21 Astrazeneca Ab New compounds 2
SE0403117D0 (sv) 2004-12-21 2004-12-21 Astrazeneca Ab New compounds 1
MX2007007818A (es) 2004-12-22 2007-09-11 Theravance Inc Compuestos de indazol-carboxamida.
SE0403171D0 (sv) 2004-12-23 2004-12-23 Astrazeneca Ab New compounds
RU2007125622A (ru) 2005-01-14 2009-02-20 Ф. Хоффманн-Ля Рош Аг (Ch) Производные тиазол-4-карбоксамида в качестве антагонистов mclur5
CN101103028A (zh) 2005-01-14 2008-01-09 神经能质公司 经杂芳基取代的喹啉-4-基氨类似物
WO2006078907A1 (en) 2005-01-20 2006-07-27 Amgen Inc. 2-substituted benzimidazole derivatives as vanilloid receptor ligands and their use in treatments
WO2006089311A1 (en) 2005-02-15 2006-08-24 Amgen Inc. Vanilloid receptor ligands and their use in treatments
EP1848716A1 (en) 2005-02-17 2007-10-31 Theravance, Inc. Crystalline form of an indazole-carboxamide compound
GB0503646D0 (en) 2005-02-22 2005-03-30 Novartis Ag Organic compounds
US8138334B2 (en) 2005-03-03 2012-03-20 Janssen Pharmaceutica N.V. Substituted oxa-diaza-spiro-[5.5]-undecanone derivatives and their use as neurokinin antagonists
MX2007011105A (es) 2005-03-10 2007-10-08 Pfizer Compuestos de n-sulfonilaminofeniletil-2-fenoxiacetamida sustituidos.
US20060211710A1 (en) 2005-03-17 2006-09-21 Pfizer Inc Substituted aryl 1,4-pyrazine derivatives
EP1863756A1 (en) 2005-03-24 2007-12-12 Janssen Pharmaceutica N.V. Biaryl derived amide modulators of vanilloid vr1 receptor
GB0506147D0 (en) 2005-03-24 2005-05-04 Merck Sharp & Dohme Therapeutic agents
US20060293309A1 (en) 2005-03-28 2006-12-28 Dynogen Pharmaceuticals, Inc. Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors
TWI377206B (en) 2005-04-06 2012-11-21 Theravance Inc Crystalline form of a quinolinone-carboxamide compound
EP1877400A1 (en) 2005-04-15 2008-01-16 Amgen, Inc Vanilloid receptor ligands and their use in treatments
GB0508314D0 (en) 2005-04-25 2005-06-01 Novartis Ag Organic compounds
WO2006116563A1 (en) 2005-04-25 2006-11-02 Amgen Inc. Vanilloid receptor ligands and their use in treatments
GB0508319D0 (en) 2005-04-25 2005-06-01 Novartis Ag Organic compounds
GB0508318D0 (en) 2005-04-25 2005-06-01 Novartis Ag Organic compounds
EP1881988A1 (en) 2005-05-11 2008-01-30 MERCK SHARP & DOHME LTD. 2,3-substituted fused bicyclic pyrimidin-4(3h)-ones modulating the function of the vanilloid-1 receptor (vr1)
US7504520B2 (en) 2005-05-11 2009-03-17 Abbott Laboratories Antagonists of the vanilloid receptor subtype 1 (VR1) and use thereof
GB0509573D0 (en) 2005-05-11 2005-06-15 Merck Sharp & Dohme Therapeutic compounds
MX2007013931A (es) 2005-05-12 2008-01-11 Amgen Inc Agentes antipireticos contra incrementos en la temperatura corporal inducidos por antagonista del receptor vainilloide 1.
NZ564254A (en) 2005-05-18 2011-04-29 Addex Pharma Sa Substituted oxadiazole derivatives as positive allosteric modulators of metabotropic glutamate receptors
DE102005023588A1 (de) 2005-05-18 2006-11-23 Grünenthal GmbH Salze substituierter Allophansäureester und deren Verwendung in Arzneimitteln
DE102005038947A1 (de) 2005-05-18 2006-11-30 Grünenthal GmbH Substituierte Benzo[d]isoxazol-3-yl-amin-Verbindungen und deren Verwendung in Arzneimitteln
GB0510139D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
GB0510142D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds A1
GB0510140D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B2
GB0510141D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B3
DE102005023784A1 (de) 2005-05-19 2006-11-30 Grünenthal GmbH Substituierte Spiro-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
DE102005044813A1 (de) 2005-05-19 2007-10-04 Grünenthal GmbH Substituierte Spiro-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
DE102005044814A1 (de) 2005-05-19 2006-11-23 Grünenthal GmbH Substituierte Sprio-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
DE102005024012A1 (de) 2005-05-20 2006-11-23 Grünenthal GmbH Verwendung von 2,5-disubstituierten Thiazol-4-on-Derivaten in Arzneimitteln
US7582611B2 (en) 2005-05-24 2009-09-01 Pfizer Inc. Motilide compounds
MY147756A (en) 2005-05-25 2013-01-15 Theravance Inc Benzimidazole-carboxamide compounds as 5-ht4 receptor agonists
US7317022B2 (en) 2005-06-07 2008-01-08 Theravance, Inc. Benzoimidazolone-carboxamide compounds as 5-HT4 receptors agonists
JP2008545801A (ja) 2005-06-10 2008-12-18 エリクシアー ファーマシューティカルズ， インコーポレイテッド スルホンアミド化合物およびその使用
JP2008546768A (ja) 2005-06-23 2008-12-25 アストラゼネカ・アクチエボラーグ 胃腸疾患を治療するためのニューロキニン受容体アンタゴニストとしての新規なアゼチジン誘導体
MX2007015606A (es) 2005-06-23 2008-02-25 Astrazeneca Ab Nuevos derivados de azetidina como antagonistas del receptor de neuroquinina para el tratamiento de enfermedades gastrointestinales.
EP1907376A2 (en) 2005-07-05 2008-04-09 Aryx Therapeutics, Inc. Stereoisomeric pyridyl and pyridonyl compounds and methods for the treatment of gastrointestinal and central nervous system disorders
US20090170872A1 (en) 2005-07-05 2009-07-02 Orchid Research Laboratories Limited Compounds and Their Pharmaceutical Use
JP2009501199A (ja) 2005-07-12 2009-01-15 グラクソ グループ リミテッド Ｇｐｒ３８アゴニストとしてのピペラジンヘテロアリール誘導体
DE602006010563D1 (de) 2005-07-22 2009-12-31 Pfizer Indazolcarbonsäureamidderivate als agonisten des 5ht4-rezeptors
US8138218B2 (en) 2005-07-22 2012-03-20 Ipsen Pharma S.A.S. Growth hormone secretagogues
HRP20120833T1 (hr) 2005-07-26 2012-11-30 Glaxo Group Limited Derivati benzilpiperazina, korisni u lijeäśenju gastrointestinalnih poremeä†aja
EP1757290A1 (en) 2005-08-16 2007-02-28 Zentaris GmbH Novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors
CA2619650A1 (en) 2005-08-19 2007-02-22 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
WO2007023242A1 (en) 2005-08-24 2007-03-01 Merz Pharma Gmbh & Co. Kgaa Tetrahydroquinolinones and their use as modulators of metabotropic glutamate receptors
EP1943247A1 (en) 2005-08-25 2008-07-16 Merz Pharma GmbH & Co.KGaA Tetrahydroquinolinones and their use as modulators of metabotropic glutamate receptors
JP2009507855A (ja) 2005-09-08 2009-02-26 スミスクライン・ビーチャム・コーポレイション 非環式１，４−ジアミンおよびその使用
KR20080043840A (ko) 2005-09-13 2008-05-19 팔라우 파르마 에스에이 히스타민 ｈ4 수용체 활성의 조정자로서 2-아미노피리미딘유도체
UY29796A1 (es) 2005-09-29 2007-04-30 Astrazeneca Ab Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor
AR056087A1 (es) 2005-09-29 2007-09-19 Astrazeneca Ab Derivados de azetidina como antagonistas de receptores de neuroquina nk
AR057828A1 (es) 2005-09-29 2007-12-19 Astrazeneca Ab Compuestos derivados de azetidina, su preparacion y composicion farmaceuutica
HUP0500920A2 (en) 2005-10-05 2007-07-30 Richter Gedeon Nyrt Oxadiazole derivatives, process for their preparation and their use
HUP0500921A2 (en) 2005-10-05 2007-07-30 Richter Gedeon Nyrt Tetrazole derivatives, process for their preparation and their use
EP1931681B1 (en) 2005-10-07 2012-11-14 Glenmark Pharmaceuticals S.A. Substituted benzofused derivatives and their use as vanilloid receptor ligands
JP5323485B2 (ja) 2005-10-19 2013-10-23 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 新規バニロイド受容体リガンド及医薬の製造へのその使用
US20070088073A1 (en) 2005-10-19 2007-04-19 Allergan, Inc. Method for treating pain
US7902251B2 (en) 2005-10-19 2011-03-08 Allergan, Inc. Method for treating pain
US7538110B2 (en) 2005-10-27 2009-05-26 Adolor Corporation Opioid antagonists
WO2007048643A1 (en) 2005-10-28 2007-05-03 Glaxo Group Limited Novel compound
CN101365684A (zh) 2005-10-28 2009-02-11 艾博特公司 抑制trpv1受体的吲唑衍生物
JP2007122605A (ja) 2005-10-31 2007-05-17 Fujitsu Ltd インピーダンス回路、電源装置
US20070105920A1 (en) 2005-11-08 2007-05-10 Akzo Nobel N.V. 2-(Benzimidazol-1-Yl)-N-(4-phenylthiazol-2-yl) acetamide derivatives
GB0525661D0 (en) 2005-12-16 2006-01-25 Glaxo Group Ltd Novel compounds
NL2000323C2 (nl) 2005-12-20 2007-11-20 Pfizer Ltd Pyrimidine-derivaten.
WO2007090853A1 (en) 2006-02-10 2007-08-16 Cellzome (Uk) Ltd. Enantiomers of amino pyrimidine compounds for the treatment of inflammatory disorders
WO2007090854A1 (en) 2006-02-10 2007-08-16 Cellzome (Uk) Ltd. Azetidine amino pyrimidine compounds for the treatment of inflammatory disorders
EP1829879A1 (en) 2006-02-10 2007-09-05 Cellzome (UK) Ltd. Amino pyrimidine compounds for the treatment of inflammatory disorders
GB0603550D0 (en) 2006-02-22 2006-04-05 Glaxo Group Ltd Novel compounds
WO2007101158A2 (en) 2006-02-24 2007-09-07 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US20090305993A1 (en) 2006-02-24 2009-12-10 Ironwood Pharmaceuticals, Inc. Methods and composition for the treatment of gastrointestinal disorders
US8597562B2 (en) 2006-03-30 2013-12-03 GM Global Technology Operations LLC Composite products and methods of making the same
UA95949C2 (ru) 2006-03-31 2011-09-26 Янссен Фармацевтика, Н.В. Бензоимидазол-2-илпиримидины и пиразины как модуляторы рецептора гистамина h4
EP2013178A1 (en) 2006-03-31 2009-01-14 Glaxo Group Limited Piperazine derivatives as growth hormone secretagogue (ghs) receptor agonists
AU2007235577B2 (en) 2006-03-31 2011-09-15 Janssen Pharmaceutica N.V. Benzoimidazol-2-yl pyridines as modulators of the histamine H4 receptor
WO2007117401A2 (en) 2006-04-07 2007-10-18 Janssen Pharmaceutica N.V. Indoles and benzoimidazoles as modulators of the histamine h4 receptor
US20100179168A1 (en) 2006-04-13 2010-07-15 Emma Louise Blaney Aryl and heteroaryl sulphonamides as growth hormone secretagogue receptor agonists
JP5028484B2 (ja) 2006-06-28 2012-09-19 グラクソ グループ リミテッド Ｇｐｒ３８受容体媒介疾患の治療に有用なピペラジニル誘導体
US8088733B2 (en) 2006-07-06 2012-01-03 Tranzyme Pharma Inc. Methods of using macrocyclic agonists of the ghrelin receptor for treatment of gastrointestinal motility disorders
WO2008083070A1 (en) * 2006-12-29 2008-07-10 Neurogen Corporation Crf1 receptor ligands comprising fused bicyclic heteroaryl moieties
AU2008241532A1 (en) 2007-02-09 2008-10-30 Tranzyme Pharma, Inc. Macrocyclic ghrelin receptor modulators and methods of using the same
EP2185553B1 (en) 2007-08-27 2012-06-27 Theravance, Inc. Amidoalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
US7691878B2 (en) 2007-08-27 2010-04-06 Theravance, Inc. Heteroarylalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
TWI423801B (zh) 2007-08-27 2014-01-21 Theravance Inc 作為μ類鴉片受體拮抗劑之８－氮雜雙環〔３．２．１〕辛基－２－羥基苯甲醯胺化合物
ES2364686T3 (es) 2007-08-27 2011-09-12 Theravance, Inc. Compuestos de alquil-8-azabiciclo[3.2.1]octano disustituidos como antagonistas del receptor opioide mu.
DE102008022221A1 (de) * 2008-05-06 2009-11-12 Universität des Saarlandes Inhibitoren der humanen Aldosteronsynthase CYP11B2
US8273900B2 (en) * 2008-08-07 2012-09-25 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
WO2011092293A3 (en) 2011-10-20
WO2011092293A2 (en) 2011-08-04
US20110201629A1 (en) 2011-08-18

Similar Documents

Publication Publication Date Title
AR080056A1 (es) Derivados de ciclohexil-amida como antagonistas de los receptores de crf
EA201591429A1 (ru) 2,3-дизамещенные производные 1-ацил-4-амино-1,2,3,4-тетрагидрохинолинов и их применение в качестве ингибиторов бромодомена
AR073136A1 (es) Compuestos de pirrol
AR072969A1 (es) Derivados de ciclohexilamida, composiciones farmaceuticas y usos como antagonistas del receptor del factor de liberacion de corticotropina (crf - 1)
EA201591703A1 (ru) Замещенные 2-азабициклы и их применение в качестве модуляторов рецепторов орексина
PE20161405A1 (es) Analogos de cortistatina y sintesis y usos de los mismos
PE20161476A1 (es) Derivados de indolin-2-ona o pirrolo-piridin-2-ona
AR054024A1 (es) Derivados de piridina -3- carboxamida como agonistas inversos de cb1
AR080314A1 (es) Derivado de 1,3,4,8-tetrahidro-2h-pirido (1,2-a) pirazina y su uso como inhibidor de la hiv integrasa
PE20142456A1 (es) COMPUESTOS DE OXAZOLIDIN-2-ONA Y USOS DE LOS MISMOS COMO INHIBIDORES DE LA PI3Ks
NI201500129A (es) 7-azabiciclos sustituidos y su uso como moduladores del receptor de orexina.
AR085615A1 (es) Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen
PE20150220A1 (es) Compuestos de tetrahidropirazolopirimidina
PE20161064A1 (es) Derivado de sulfonamida o sales de adicion de acido farmaceuticamente aceptables del mismo
ECSP099324A (es) Nuevos derivados de aminopirimidina como inhibidores de plk1
AR080496A1 (es) Inhibidores heterociclicos de los receptores de histamina para el tratamiento de una enfermedad
PE20140934A1 (es) Derivados de pirazol
PE20141211A1 (es) Moduladores receptores de hormonas nucleares
PE20171057A1 (es) Derivados espirodiamina como inhibidores de la aldosterona sintasa
AR091519A1 (es) Inhibidores pirrolopirazona de tanquirasa
AR086198A1 (es) Inhibidores sustituidos de acetil-coa carboxilasa y composiciones farmaceuticas que los contienen
AR069480A1 (es) Derivados de 2-amino-pirimidina
EA201171062A1 (ru) Алкиламидные соединения и их применение
ES2626801T3 (es) Compuestos de triazolopiridina como inhibidores de pde10a
PE20151060A1 (es) Nuevos derivados de pirazina como agonistas del receptor cb2

Legal Events

Date Code Title Description
FB Suspension of granting procedure